MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
-First placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint
-Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting a new bar in HS
-HiSCR50 met with 38 ppt delta vs placebo (p
-First placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint
-Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting a new bar in HS
-HiSCR50 met with 38 ppt delta vs placebo (p
- Contact Email
- [email protected]
- Issued By
- Knowledge Bylanes
- Business Address
- Press Centre
Karachi Pakistan - Country
- Pakistan
- Categories
- Miscellaneous
- Last Updated
- June 27, 2023